KPP Advisory Services LLC Boosts Position in abrdn Life Sciences Investors $HQL

KPP Advisory Services LLC boosted its position in shares of abrdn Life Sciences Investors (NYSE:HQL) by 7.7% in the second quarter, Holdings Channel reports. The fund owned 23,555 shares of the company’s stock after purchasing an additional 1,681 shares during the quarter. KPP Advisory Services LLC’s holdings in abrdn Life Sciences Investors were worth $302,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently bought and sold shares of the company. Stratos Wealth Partners LTD. increased its position in abrdn Life Sciences Investors by 7.4% during the first quarter. Stratos Wealth Partners LTD. now owns 14,176 shares of the company’s stock valued at $180,000 after acquiring an additional 971 shares during the last quarter. Kingsview Wealth Management LLC increased its position in abrdn Life Sciences Investors by 3.1% during the first quarter. Kingsview Wealth Management LLC now owns 35,743 shares of the company’s stock valued at $454,000 after acquiring an additional 1,060 shares during the last quarter. Private Advisor Group LLC increased its position in abrdn Life Sciences Investors by 5.0% in the first quarter. Private Advisor Group LLC now owns 23,075 shares of the company’s stock worth $293,000 after buying an additional 1,097 shares in the last quarter. Blue Bell Private Wealth Management LLC increased its position in abrdn Life Sciences Investors by 2.2% in the first quarter. Blue Bell Private Wealth Management LLC now owns 63,569 shares of the company’s stock worth $807,000 after buying an additional 1,359 shares in the last quarter. Finally, Stephens Inc. AR increased its position in abrdn Life Sciences Investors by 9.8% in the second quarter. Stephens Inc. AR now owns 21,231 shares of the company’s stock worth $272,000 after buying an additional 1,895 shares in the last quarter. Hedge funds and other institutional investors own 32.21% of the company’s stock.

abrdn Life Sciences Investors Stock Performance

Shares of HQL opened at $16.37 on Friday. The business has a 50-day simple moving average of $14.84 and a two-hundred day simple moving average of $13.39. abrdn Life Sciences Investors has a 52 week low of $10.55 and a 52 week high of $16.92.

abrdn Life Sciences Investors Cuts Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Friday, August 22nd were given a $0.42 dividend. The ex-dividend date was Friday, August 22nd. This represents a $1.68 dividend on an annualized basis and a yield of 10.3%.

Insider Buying and Selling

In other abrdn Life Sciences Investors news, major shareholder Saba Capital Management, L.P. sold 41,623 shares of the company’s stock in a transaction dated Monday, September 22nd. The stock was sold at an average price of $14.14, for a total value of $588,549.22. Following the completion of the sale, the insider owned 2,837,633 shares in the company, valued at $40,124,130.62. This represents a 1.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders sold a total of 179,906 shares of company stock valued at $2,530,720 in the last three months. Corporate insiders own 10.06% of the company’s stock.

About abrdn Life Sciences Investors

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.